StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) stock

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.00−0.08 (-3.85%)

Close on Nov 19, 2026Market cap $109.54MP/E –Yield –

Upstream Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Upstream Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$133.44M. For fiscal 2025 it was -$133.44M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$133.44M–
FY2024Dec 31, 2024-$59.68M–
FY2023Dec 31, 2023-$38.07M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$54.23M–
Q4 FY2025Dec 31, 2025-$30.69M–
Q3 FY2025Sep 30, 2025-$22.30M–
Q4 FY2024Dec 31, 2024-$19.80M–
Q4 FY2023Dec 31, 2023-$16.11M–

More Upstream Bio figures

See a number that looks wrong?